TW202016110A - Ｊａｋ激酶家族之小分子抑制劑 - Google Patents

Ｊａｋ激酶家族之小分子抑制劑 Download PDF

Info

Publication number
TW202016110A
TW202016110A TW108120432A TW108120432A TW202016110A TW 202016110 A TW202016110 A TW 202016110A TW 108120432 A TW108120432 A TW 108120432A TW 108120432 A TW108120432 A TW 108120432A TW 202016110 A TW202016110 A TW 202016110A
Authority
TW
Taiwan
Prior art keywords
compound
diffraction pattern
suspension
jak
solvent
Prior art date
Application number
TW108120432A
Other languages
English (en)
Chinese (zh)
Inventor
菲利浦 費南德斯
保羅 克拉祖克
馬克 蒂奇諾
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202016110A publication Critical patent/TW202016110A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
TW108120432A 2018-06-15 2019-06-13 Ｊａｋ激酶家族之小分子抑制劑 TW202016110A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862685737P 2018-06-15 2018-06-15
US62/685,737 2018-06-15
US201962846290P 2019-05-10 2019-05-10
US62/846,290 2019-05-10

Publications (1)

Publication Number Publication Date
TW202016110A true TW202016110A (zh) 2020-05-01

Family

ID=67766195

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108120432A TW202016110A (zh) 2018-06-15 2019-06-13 Ｊａｋ激酶家族之小分子抑制劑

Country Status (23)

Country Link
US (3) US20200017498A1 (https=)
EP (1) EP3807277A1 (https=)
JP (1) JP2021528391A (https=)
KR (1) KR102768284B1 (https=)
CN (1) CN112313233A (https=)
AU (1) AU2019286641A1 (https=)
BR (1) BR112020024744A2 (https=)
CA (1) CA3101438A1 (https=)
CL (1) CL2020003227A1 (https=)
CO (1) CO2020015396A2 (https=)
CR (1) CR20200603A (https=)
EC (1) ECSP20080817A (https=)
IL (1) IL279314A (https=)
JO (1) JOP20200311A1 (https=)
MA (1) MA52900A (https=)
MX (1) MX2020013688A (https=)
NI (1) NI202000100A (https=)
PE (1) PE20212113A1 (https=)
PH (1) PH12020551984A1 (https=)
SG (1) SG11202011691PA (https=)
TW (1) TW202016110A (https=)
UY (1) UY38262A (https=)
WO (1) WO2019239387A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
BR112023018286A2 (pt) * 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA67844C2 (uk) 1999-04-23 2004-07-15 Смітклайн Бічам Плс Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MXPA04011865A (es) 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
EP1902029B2 (en) 2005-07-01 2022-02-16 Wyeth LLC Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
JP5567137B2 (ja) 2009-09-03 2014-08-06 ブリストル−マイヤーズ スクイブ カンパニー Ｊａｋ２阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
PE20121336A1 (es) 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2534258B1 (en) 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja) 2014-05-14 2015-11-19 日産化学工業株式会社 ３環性化合物及びｊａｋ阻害剤
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TWI735681B (zh) 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
EP3555064B9 (en) 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045224A1 (en) 2016-12-16 2018-06-21 Basf Se Pesticidal compounds
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
KR102276022B1 (ko) 2016-12-16 2021-07-13 일라이 릴리 앤드 캄파니 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3528645A1 (en) 2016-12-16 2019-08-28 Société des Produits Nestlé S.A. Oligosaccharides for flavour generation
PL3568396T3 (pl) 2017-01-11 2021-05-31 Leo Pharma A/S Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne
PT3494116T (pt) 2017-01-30 2020-01-28 Astrazeneca Ab Moduladores de recetores de estrogénio
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
US20200017498A1 (en) 2020-01-16
US11066406B2 (en) 2021-07-20
EP3807277A1 (en) 2021-04-21
US20210340144A1 (en) 2021-11-04
JP2021528391A (ja) 2021-10-21
CR20200603A (es) 2021-01-20
NI202000100A (es) 2021-06-30
BR112020024744A2 (pt) 2021-03-23
KR20210021342A (ko) 2021-02-25
PH12020551984A1 (en) 2021-08-02
UY38262A (es) 2019-12-31
US20200165250A1 (en) 2020-05-28
IL279314A (en) 2021-01-31
WO2019239387A1 (en) 2019-12-19
JOP20200311A1 (ar) 2020-11-30
MA52900A (fr) 2021-04-21
KR102768284B1 (ko) 2025-02-13
ECSP20080817A (es) 2021-01-29
CL2020003227A1 (es) 2021-05-14
CA3101438A1 (en) 2019-12-19
PE20212113A1 (es) 2021-11-04
MX2020013688A (es) 2021-02-26
CO2020015396A2 (es) 2021-03-08
US11787807B2 (en) 2023-10-17
AU2019286641A1 (en) 2020-12-10
SG11202011691PA (en) 2020-12-30
CN112313233A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
TWI777997B (zh) Ｊａｋ激酶家族之小分子抑制劑
TWI726094B (zh) 作為jak激酶抑制劑之嘧啶化合物
TW202016110A (zh) Ｊａｋ激酶家族之小分子抑制劑
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
TW202446369A (zh) 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
UA126394C2 (uk) Похідні бензоксазолу як імуномодулятори
WO2021115457A1 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
TW202200575A (zh) 一種免疫抑制劑、其製備方法和應用
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN105228625A (zh) 大环rip2激酶抑制剂
TW200304817A (en) Chemical compounds
JPWO2019189555A1 (ja) 複素環化合物
US20220056026A1 (en) Crystalline forms of a selective c-kit kinase inhibitor
UA121315C2 (uk) Макроциклічні інгібітори кінази rip2
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
HK40008834B (zh) Jak家族激酶的小分子抑制剂
HK40130027A (zh) 葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途
CN117820340A (zh) Atr抑制剂及其用途
CN120569387A (zh) Par2的小分子调节剂及其用途
AU2022206999A9 (en) Bridged heterocyclyl-substituted pyrimidine compounds, preparation method and medical use thereof
HK40084227B (zh) 哒嗪基噻唑甲醯胺类化合物
HK40085586B (zh) 哒嗪基噻唑甲酰胺类化合物
HK40059656B (zh) 哒嗪基噻唑甲酰胺类化合物
EA037347B1 (ru) Низкомолекулярные ингибиторы киназ семейства jak